The immunologic mechanisms mediating intraocular inflammatory diseases are largely unknown. Certain cytokines have been implicated in the pathogenesis of uveitis. For example, interleukin-2 (IL-2) in ocular tissues1 and IL-6 in aqueous2,3 have been demonstrated in several forms of intraocular inflammation. However, it is unclear whether these molecules play a primary rather than secondary role in the pathophysiologic processes of uveitis.
We report a case in which therapy with IL-3 and IL-6 was associated with the development of bilateral uveitis and decreased visual acuity.
Report of a Case.
Anemia and thrombocytopenia due to myelodysplasia (subtype refractory anemia with excess blasts) that occurred 10 months after combination chemotherapy for nodular sclerosing Hodgkin's disease developed in a 67-year-old woman. At the time of enrollment into this trial, the patient was well, was without evidence of Hodgkin's disease or infection, had no other significant medical problem, and was receiving no medications other
Wu WC, Mannion B, Stone RM. Uveitis Associated With Interleukin-3 and Interleukin-6 Therapy. Arch Ophthalmol. 1995;113(4):408–409. doi:10.1001/archopht.1995.01100040022013
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.